share_log

Brian Blaser Buys Handful Of Shares In QuidelOrtho

Brian Blaser Buys Handful Of Shares In QuidelOrtho

布赖恩·布拉泽购买了窥得儿医药的一小部分股票
Simply Wall St ·  12/15 21:19

Investors who take an interest in QuidelOrtho Corporation (NASDAQ:QDEL) should definitely note that the President, Brian Blaser, recently paid US$41.42 per share to buy US$250k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.

对窥得儿医药公司(纳斯达克:QDEL)感兴趣的投资者应该特别注意,总裁布莱恩·布雷泽(Brian Blaser)最近以每股41.42美元的价格购买了价值25万美元的股票。 然而,这仅仅增加了少量的参股金融,而且在绝对值上也不是一笔巨大的购买。

The Last 12 Months Of Insider Transactions At QuidelOrtho

窥得儿医药过去12个月的内部交易

Notably, that recent purchase by Brian Blaser is the biggest insider purchase of QuidelOrtho shares that we've seen in the last year. That means that even when the share price was higher than US$41.35 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

值得注意的是,布莱恩·布雷泽最近的购买是我们在过去一年中看到的窥得儿医药内部人士最大的一次股票购买。这意味着即使在股价高于41.35美元(最近价格)时,内部人士也想购买股票。他们很可能对这笔购买感到后悔,但更有可能是对公司看好。我们始终仔细关注内部人士购买股票时支付的价格。一般来说,当内部人士在高于当前价格的情况下购买股票时,会引起我们的注意,因为这表明他们认为股票值得在更高的价格时购买。

In the last twelve months QuidelOrtho insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

在过去的十二个月中,窥得儿医药的内部人士在购买股票,但没有出售。您可以在下面查看过去12个月内部交易的可视化图示。通过点击下面的图表,您可以查看每个内部交易的具体细节!

big
NasdaqGS:QDEL Insider Trading Volume December 15th 2024
纳斯达克GS:QDEL 内部交易成交量 2024年12月15日

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

还有很多其他公司内部人士正在买入股票。你可能不想错过这份内部人士正在购买的被低估的小盘公司的免费名单。

Does QuidelOrtho Boast High Insider Ownership?

窥得儿医药是否拥有高内部所有权?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that QuidelOrtho insiders own 5.5% of the company, worth about US$154m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

查看公司内部股东的总持股情况,可以帮助你了解他们是否与普通股东保持一致。 高比例的内部持股通常使公司领导层更加关注股东的利益。 很高兴看到窥得儿医药的内部人士拥有5.5%的股份,价值约为15400万美元。 我喜欢看到这样的内部持股比例,因为这增加了管理层考虑股东最佳利益的可能性。

What Might The Insider Transactions At QuidelOrtho Tell Us?

内部交易在窥得儿医药可能告诉我们什么?

The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest QuidelOrtho insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 1 warning sign for QuidelOrtho you should be aware of.

最近的内部购买让人振奋。 长期的内部交易也给予我们信心。 但另一方面,公司在过去一年中出现了亏损,这让我们感到有些谨慎。 综合考虑显著的内部持股,这些因素表明窥得儿医药的内部人士与公司目标高度一致,并且很可能认为股价过低。 至少值得加入自选。 因此,这些内部交易可以帮助我们构建关于这只股票的理论,但同样了解公司面临的风险也是值得的。 例如:我们发现了一个你应该了解的窥得儿医药的警示信号。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

当然,您也可能会在其他地方找到一个绝佳的投资。请查看这个免费的有趣公司名单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

在本文中,内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发